Diakron Pharmaceuticals, Inc. is a cardiovascular drug development company focused on clinically differentiated products for significant cardiovascular markets. Diakron will complete Phase II development of DP-4088, a direct thrombin inhibitor, and complete Phase I development of a lead T-type calcium channel blocker (TCCB).
Diakron develops unique products for the cardiovascular and related fields. Today, the focus, based on expected resources, is to develop products to an important clinical milestone and then to potentially partner, out-license or co-market to speed late-stage development and marketing. Given adequate resources, the Diakron Management Team is prepared to take the Diakron products through clinical development, registration and marketing. The Company currently has development programs targeting clotting disorders, hypertension, and diabetes.